Paediatric Solid Tumour Biology and Therapeutics Group

Professor Louis Chesler’s group is investigating the genetic causes for the childhood cancers, neuroblastoma, medulloblastoma and rhabdomyosarcoma. 

Research, projects and publications in this group

Our group's aim is to improve the treatment and survival of children with neuroblastoma, medulloblastoma and rhabdomyosarcoma.

The goal of our laboratory is to improve the treatment and survival of children with neuroblastoma, medulloblastoma and rhabdomyosarcoma, three paediatric solid tumours in which high-risk patient cohorts can be defined by alterations in a single oncogene. We focus on the role of the MYCN oncogene, since aberrant expression of MYCNis very significantly associated with high-risk in all three diseases and implies that they may have a common cell-of-origin.

Elucidating the molecular signalling pathways that control expression of the MYCN oncoprotein and targeting these pathways with novel therapeutics is a major goal of the laboratory. We use a variety of innovative preclinical drug development platforms for this purpose.

Technologically, we focus on genetically engineered cancer models incorporating novel imaging (optical and fluorescent) modalities that can be used as markers to monitor disease progression and therapeutic response.

Our group has several key objectives:

  • Mechanistically dissect the role of the MYCN oncogene, and other key oncogenic driver genes in poor-outcome paediatric solid tumours (neuroblastoma, medulloblastoma, rhabdomyosarcoma).
  • Develop novel therapeutics targeting MYCN oncoproteins and other key oncogenic drivers
  • Develop improved genetic cancer models dually useful for studies of oncogenesis and preclinical development of novel therapeutics.
  • Use such models to develop and functionally validate optical imaging modalities useful as surrogate markers of tumour progression in paediatric cancer.

Professor Louis Chesler

Clinical Senior Lecturer/Group Leader:

Paediatric Solid Tumour Biology and Therapeutics Professor Louis Chesler (Profile pic)

Professor Louis Chesler is working to understand the biology of children’s cancers and use that information to discover and develop new personalised approaches to cancer treatment. His work focuses on improving the understanding of the role of the MYCN oncogene.

Researchers in this group

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6124

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 3617

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4186

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 3501

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4361

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6118

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6021

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6196

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6258

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6121

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4527

Email: [email protected]

Location: Sutton

.

OrcID: 0000-0003-3977-7020

Phone: +44 20 3437 6109

Email: [email protected]

Location: Sutton

I obtained an MSci in Biochemistry from the University of Glasgow in 2018. In October 2018 I joined the labs of Dr Michael Hubank and Professor Andrea Sottoriva to investigate the use of liquid biopsy to monitor clonal frequency and emergence of resistance mutations in paediatric cancers.

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6358

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6131

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

Professor Louis Chesler's group have written 112 publications

Most recent new publication 1/2025

See all their publications

Vacancies in this group

Working in this group

Postdoctoral Training Fellow

  • Chelsea
  • Structural Biology
  • Salary Range: £38,700 - £45,500 per annum
  • Fixed term

Under the leadership of Claudio Alfieri, we are seeking to appoint a Postdoctoral Training Fellow to join the Molecular Mechanisms of Cell Cycle Regulation Group at the Chester Beatty Laboratories, Fulham Road in London. This project aims to investigate the molecular mechanisms of cell cycle regulation by macromolecular complexes involved in cell proliferation decisions, by combining genome engineering, proteomics and in situ structural biology. For general information on Post Doc's at The ICR can be found here. Key Requirements The successful candidate must have a PhD in cellular biochemistry and experience in Cryo-EM and CLEM is desirable. The ICR has a workforce agreement stating that Postdoctoral Training Fellows can only be employed for up to 7 years as PDTF at the ICR, providing total postdoctoral experience (including previous employment at this level elsewhere) does not exceed 10 years Department/Directorate Information: The candidate will work in the Molecular Mechanisms of Cell Cycle Regulation Group within the ICR Division of Structural Biology headed by Prof. Laurence Pearl and Prof. Sebastian Guettler. The division has state-of-the-art facilities for protein expression and biophysics/x-ray crystallography, in particular the Electron Microscopy Facility is equipped with a Glacios 200kV with Falcon 4i detector with Selectris energy filter and the ICR has access to Krios microscopes via eBIC and the LonCEM consortium. We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Claudio Alfieri via Email on [email protected]

Postdoctoral Training Fellow – X-Ray Crystallography

  • Sutton
  • Hit Discovery & Structural Design
  • £45,600 - £51,450
  • Fixed term

A postdoctoral position is available in Dr Rob van Montfort’s Hit Discovery and Structural Design Team within the CCDD. The Post-doc will be involved in the structure determination of protein-ligand complexes, primarily by X-ray crystallography but also potentially by cryo-electron microscopy (cryoEM), as part of one of the CCDD’s drug discovery programmes. The postholder will be responsible for protein production and purification, protein crystallisation, structure determination by X-ray crystallography and subsequent structural analysis. The successful candidate will be an integral member of a multidisciplinary project team within the CCDD at the ICR Sutton site, and will interact closely with biologists, computational chemists, medicinal chemists, assay scientists and structural biologists.They will have access to state-of-the-art facilities for protein production and purification, as well as biophysical characterisation and crystallisation at the Sutton site. We also benefit from excellent access to Diamond Light Source synchrotron at the Harwell Science and Innovation campus, Didcot, UK, for X-ray data collection. Additionally, the successful candidate will also be part of the Division of Structural Biology, located in Chelsea, in which the structural biologists in Dr van Montfort’s team are also embedded, and will have access to its state-of-the art cryoEM facilities. These include an in-house Glacios and 30% direct access to a Titan KRIOS located at the Francis Crick Institute. Both microscopes are equipped with Falcon III detectors and volta phase plates (VPP). In addition, we have excellent access to the electron bioimaging Centre (eBIC) at the Harwell Science and Innovation campus, Didcot, UK. About you The successful candidate must have must have a PhD (or equivalent) in a biological or physical science, with demonstrable experience in X-ray crystallography and protein biochemistry. Experience in cryo-EM specimen preparation and data processing would be an advantage, though not strictly mandatory. Experience in molecular biology, protein expression and purification, as well as biophysical characterisation of protein samples would also be highly desirable. The ICR has a workforce agreement stating that Postdoctoral Training Fellows can only be employed for up to 7 years as PDTF (including previous employment at this level elsewhere). For general information on Postdocs at The ICR, more information can be found here. Department/Directorate Information The Institute of Cancer Research (ICR), London, is one of the world’s most influential cancer research institutes, with an outstanding record of achievements dating back more than 100 years. We provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today, the ICR leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment. Together with our hospital partner The Royal Marsden, we are rated in the top four centres for cancer research and treatment worldwide. As well as being a world-class institute, we are a college of the University of London. We came top in the league table of university research quality compiled from the Research Excellence Framework in 2014 and second in 2021 (REF 2014 and 2021). The ICR is committed to attracting, developing and retaining the best minds in the world to join us in our mission – to make the discoveries that defeat cancer. Department/Directorate Information: The Centre for Cancer Drug Discovery (CCDD), within the Division of Cancer Therapeutics, is a multidisciplinary 'bench to bedside' centre, comprising around 160 staff dedicated to the discovery and development of novel therapeutics for the treatment of cancer. The CCDD’s exciting goal is to discover high quality small molecule drug candidates and to progress these to clinical trial. All the scientific disciplines are in place to make this possible, including medicinal chemistry, biology, structural biology, assay scientists, drug metabolism and clinical specialists. This is an exciting and fast-moving research setup and offers the opportunity to work within a multi-disciplinary environment using state-of-the-art techniques and equipment. What we offer A dynamic and supportive research environment Access to state-of-the-art facilities and professional development opportunities Collaboration with leading researchers in the field Competitive salary and pension We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Dr van Montfort [email protected] or Dr Le Bihan [email protected]. Please DO NOT send your application to Dr Van Montfort or Dr Le Bihan, but apply via the e-recruitment system on our websitewww.icr.ac.uk/careers.

Industrial partnership opportunities with this group

Opportunity: A novel test for predicting future cancer risk in patients with inflammatory bowel disease

Commissioner: Professor Trevor Graham

Recent discoveries from this group

02/01/25

 A ‘TripAdvisor-style’ website that helps scientists choose the best small-molecule tools for their experiments has been greatly expanded to include expert reviews of hundreds of chemical probes that can be used to increase the robustness of fundamental and applied research and help develop an arsenal of new cancer drugs.

First launched in 2015 to combat the widespread use of low-quality compounds, The Chemical Probes Portal is aimed at improving the quality and robustness of biomedical experimentation, including both fundamental ‘blue-sky’ research as well as more applied translational studies, including drug discovery.

A new research article, published in the special 2024 database issue of Nucleic Acids Research, summarises the major updates in the content and functionality of the Portal, which now provides information and free expert advice on more than 800 chemical probes. The Portal also features updated guidelines to support scientists in choosing the best small-molecule probes for their protein and using them appropriately.

A one-stop trusted resource

Chemical probes are powerful and versatile tools for determining the function in experimental systems of a particular protein of interest to a researcher. However, to be useful, they must be of high quality – as judged by their potency for the desired protein target and their molecular selectivity (for example, having as few effects as possible on ‘off-target’ proteins) together with evidence of modulating the protein of interest in intact cells.

Unfortunately, the vast amount of information on chemical probes is scattered across a huge number of research articles and other sources, making it challenging for researchers to access and distil the data they require. The Chemical Probes Portal is a trusted one-stop resource designed specially to help researchers make the decisions needed for their own work.

A unique feature of the Portal is that probes are reviewed by a large panel of international experts. Each probe is given a ‘TripAdvisor-style’ star rating, ranging from one to four stars (with four stars being the highest score), designed to help researchers assess the suitability of chemical probes for use in biological and biomedical research. Around 85% of probes reviewed on the Portal are rated as having three or four stars, meaning that they can be used with especially high confidence in biological experiments.

As well as the star ratings, the expert reviewers also provide a range of comments – for example on the concentrations at which the probes should be used, any experimental control compounds that should ideally be included alongside the probe (both inactive analogues and additional active tools, if available) along with any caveats that users should be aware of.

Finding new drug targets

The Portal, which is hosted by The Institute of Cancer Research, London and funded mainly by Wellcome, was set up by an international group of leading scientists, to address a major problem with the use of chemical probes in biomedical research.

 Chemical probes play an important role by helping researchers to understand the normal function of specific proteins in healthy physiology of cells and model organisms. They are complementary to, and have some advantages over, orthogonal genetic technologies such as RNA interference and CRISPR – for example, providing more versatile control of concentration- and time-dependent perturbation of the desired target.

Importantly, these small-molecule research tools can help determine which proteins are involved in a disease, making them potentially suitable for therapeutic modulation. By inhibiting or modifying the activity of such specific proteins, chemical probes can show researchers whether targeting them could be effective in treating the disease.

Addressing a major problem in research

But despite considerable progress in recent years in the availability and application of these small molecules, researchers across the world are frequently still using poor-quality compounds even when newer, better compounds become available and are also not following consensus best practice in their use. This results in misleading research conclusions, wasted resources and even wrong decisions and delays in drug development.

Using the wrong molecule, for example, a broad kinase inhibitor such as staurosporine rather than a selective inhibitor of the protein of interest, makes it impossible to understand what is happening in the cell, as multiple targets are affected at the same time. And using a probe at too high a concentration and without suitable controls can increase the risk of non-specific effects.

When it was first launched almost a decade ago, the Portal had only a limited number of probes and covered a restricted range of protein families.

However, with dedicated funding and support from the global scientific community, the number and diversity of probes has increased. The latest update reports that the Portal now includes 803 expert-annotated chemical probes, representing a huge expansion over the original number in 2015 and an impressive increase of 47 per cent from the count of 547 reported in the previous published Portal update just two years ago.

Expanding the Portal

Most of the chemical probes on the Portal act as inhibitors, but the team behind the initiative are expanding and broadening the database to include more diverse probes with different modes of action. As a result, there are now 122 classical agonists/antagonists, 28 covalent binders and 51 degraders included.

The expansion of the number and diversity of chemical probes is accompanied by a 34 per cent increase in the coverage of human protein targets, rising to 570 from 425 in 2022. The range of target families and disease applications of the probes has also increased, including those acting on protein targets relevant to neurological diseases such as Alzheimer's and Parkinson's, as well as diabetes.

This broader disease coverage is crucial for researchers working in areas outside oncology, which has traditionally been relatively well-served, as compared to the comparatively fewer high-quality chemical probes that are available to researchers working on certain other disorders, especially neurodegenerative diseases. This is an area of future focus for the Portal, although chemical probes for cancer research will continue to be important.

Introducing ‘The Unsuitables’

In addition to chemical probes that justify a star rating, the Portal also highlights 258 compounds now known as ‘The Unsuitables’. These are compounds which are not appropriate for use as chemical probes to investigate the function of any one particular protein in cells or organisms.

Once known as ‘Historical Compounds’, these are small molecules that are not fit to be used as high-quality chemical probes. Although many of these compounds may once have been useful as pathfinders, they are no longer suitable for this purpose because other, higher-quality chemical probes are now recommended instead. Others have long been recognised as promiscuously active and should never have been used as chemical probes.

To further enhance the Portal, user-friendly connectivity with other useful resources such as canSAR is being automated. A very important, independent, public translational resource in its own right, canSAR also supplies valuable up-to-date technical information on chemical probes to the Portal’s expert reviewers and users. It was created by Professor Bissan AL-Lazikani, formerly Head of Data Science at the ICR, now at MD Anderson Cancer Centre in Houston, Texas where canSAR is hosted – who is also a member of the Portal leadership team.

canSAR combines data from various sources and uses AI to create new insights. A recent sister paper to the Portal publication, also published in the 2024 database issue of Nucleic Acids Research, describes how canSAR has added more data and updated its algorithms. These updates include enhanced tools for finding drug targets, including incorporation of AlphaFold 2 models, and a new system for organising chemical data.

Looking to the future, The Chemical Probes Portal will work with the Target 2035 initiative  to support acceleration toward the challenge of developing a chemical probe for every human protein. In addition, the Portal will continue to run its highly successful Hackathon events to help introduce chemical probes to early career researchers, while also getting batches of reviews of chemical probes completed under the supervision of experienced experts.

Professor Paul Workman, Harrap Professor of Pharmacology and Therapeutics at The Institute of Cancer Research, London, who is also Executive Director of the Chemical Probes Portal and senior author of the Nucleic Acids Research Portal update paper, said:

"Chemical probes are super important for studying protein functions and developing new treatments for diseases. However, if poorly selected or misused in experiments, they can lead to incorrect or misleading results. Yet researchers face a formidable challenge in finding the information they need to select and use the best chemical probe for their work.

“The Chemical Probes Portal is a free resource designed to help the biomedical research community by offering expert advice on the best tools for a given protein of interest and on their optimal usage in experiments. High-quality chemical probes are recommended by experts based on well-established criteria such as high potency and selectivity towards the target protein, broad target profiling showing the minimal possible off-target effects, and evidence supporting modulation of the protein’s function in living cells.

“We are excited that our latest updates to the content and functionality of the Portal will further enhance the selection and use of the best tools for experimental research, thereby helping the research community to improve the quality and reliability of basic and translational biomedical research, including drug discovery.”